XBIOTECH INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
XBIOTECH INC. (XBIT) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $10.30 per share for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-05-14
- XBIOTECH INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $15.00, a 37.36% increase year-over-year.
- XBIOTECH INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $10.92.
- XBIOTECH INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2016-09-30 was $12.98, a 8.98% decline year-over-year.
- XBIOTECH INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2016-06-30 was $8.87.
- XBIOTECH INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2015 was $11.05, a 3.95% increase from fiscal 2014.
- XBIOTECH INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2014 was $10.63, a 26.70% increase from fiscal 2013.
- XBIOTECH INC. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2013 was $8.39.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2025-09-30 | $10.30 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $12.44 10-Q · filed 2025-08-13 | |||
| 2025-03-31 | $15.00 10-Q · filed 2026-05-14 | |||
| 2024-09-30 | $10.78 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $10.88 10-Q · filed 2025-08-13 | |||
| 2024-03-31 | $10.92 10-Q · filed 2025-05-14 | |||
| 2023-09-30 | $10.73 10-Q · filed 2024-11-13 | |||
| 2016-09-30 | $12.98 10-Q · filed 2016-11-14 | |||
| 2016-06-30 | $8.87 10-Q · filed 2016-11-14 | |||
| 2016-03-31 | $11.50 10-Q · filed 2016-11-14 | |||
| 2015-12-31 | $11.05 10-K · filed 2016-04-15 | |||
| 2015-09-30 | $14.26 10-Q · filed 2015-11-13 | |||
| 2015-03-31 | $8.83 10-Q · filed 2015-11-13 | |||
| 2014-12-31 | $10.63 10-K · filed 2016-04-15 | |||
| 2013-12-31 | $8.39 10-K · filed 2016-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |